Pharmacogenomics in Brazil

摘要: Brazil, the sixth largest world economy, has a highly heterogeneous and admixed population in excess of 200 million, with biogeographical Amerindian, European, Sub-Saharan African ancestral roots. These characteristics represent caveat concerning extrapolation pharmacogenetics-genomics (PGx) data from comparatively more homogeneous populations. And it prompted creation Brazilian Pharmacogenetics Network–Refargen, consortium 20 research groups whose mission is to provide leadership PGx education Brazil ultimately improve health its population. A major challenge for studies stratification, which if not controlled for, may confound association study outcomes. Refargen researchers have developed ways deal this by combining ancestry-informative markers appropriate statistical approaches. They conducted clinical trials involving range therapeutic medicines, including antipsychotics, antiretrovirals, antituberculosis agents, clopidogrel statins, immunosuppressants renal transplant recipients; L-thyroxine thyroid cancer patients; methylphenidate attention-deficit hyperactivity disorder; nonsteroidal anti-inflammatory agents; warfarin. We review outcomes some these studies, we highlight development PGx-dosing warfarin algorithms our two groups. Adoption natural setting public system private practice faces same barriers encountered worldwide, only but PGx-informed prescriptions general. The contributes overcoming through research, educational training, consulting initiatives.